1Psaty BM, Furberg CD, Ray WA, et al. Petential for conflict of interest in the evaluation of suspected adverse drug reac- tion : use of cerivastatin and risk of rhabdomyolysis [ J ]. JA- MA ,2004,292 ( 21 ) :2655-2657.
3Kaspera R, Naraharisetti SB, Tamraz B, et al. Cerivastatin in vitro metabolism by CYP2C8 variants found in patients ex- periencing rhabdomyolysis [ J ]. Pharmacogenet Genomics, 2010,20(10) :619-629.
4Neuvonen PJ, Niemi M , Backman JT. Drug interactions with lipid- lowering drugs: Mechanisms and clinical rele- vance [ J ]. Clin Pharmacol Ther,2006, 80 ( 6 ) :565-581.
5Shitara Y, Hirano M, Sato H, et al. Gcmfibrozil and its glucu- ronide inhibit the organic anion transporting polypeptide 2 ( OATP2/OATP1BI : SLC21A6 )-mediated hepatic uptake and CYP2CS-mediated metabolism of cerivastatin:analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil[ J]. J Pharmacol Exp T- her.2004.311 ( 1 ) :228-236.
7Strandell J,Bate A, Hagg S,et al. Rhabdomylysis a result of azithromycin and statins : an unrecognized interaction [ J ]. Br J Clin Pharmaeol, 2009,68 ( 3 ): 427-434.
